Ayoxxa Biosystems said that Gerald Möller has joined its board as an independent director and as its chairman. He will guide the firm's expansion from life science research into disease-specific applications for Ayoxxa's Lunaris multiplexing technology. Möller has 40 years of management experience in the diagnostic and pharmaceutical industries and was most recently an investment advisor to HMB Partners. He held senior management positions at Boehringer Mannheim from 1975 to 1998 and became CEO of the worldwide operating group in 1995. He was also a board member at Illumina before leaving in May. He currently is chairman of Morphosys.
A. Barry Rand, Sue Rataj
Agilent Technologies announced changes to its board with the resignation of A. Barry Rand and the election of Sue Rataj.
Rand's resignation is effective Oct. 31. He has been a board member since 2000 and serves on the compensation committee and nominating/corporate governance committee. His departure is not the result of any disagreement with the firm regarding its operations, policies, or practices, Agilent said.
Meanwhile, Rataj joined the board effective Sept. 15. She was chief executive of BP's global petrochemicals business before retiring in April 2011. Before that, she was a group president at BP. Following her retirement from the firm, Rataj joined the board of Cabot and the supervisory board of Bayer.
Jonathan Zhao, Lei Li, Min Wang
Veritas Genetics has named the leaders of its Asian R&D center established inHangzhou,China. Veritas Co-founder Jonathan Zhao is the managing director, Lei Li is the vice president of global clinical and regulatory affairs, and Min Wang is the vice president of China R&D.
Zhao has more than 15 years ofAsiastrategy and product launch experience with Amgen and Pfizer. Li was recently the leader of the clinical genetics laboratory at Novartis inBoston, and previous to that held a similar position at Pfizer. Wang joins Veritas from theHumanGenomeSequencingCenterof the Baylor College of Medicine.
Signal Genetics has appointed Richard Bender its chief medical officer, effective Sept. 14. He will report directly to Signal President and CEO Samuel Riccitelli.
Bender has more than 30 years of experience in clinical oncology/hematology and medical diagnostics. Most recently, he consulted for various companies and was a long-term medical affairs consultant for Quest Diagnostics. Previous to that, he was vice president and CMO at Agendia, and before that, he was the medical director of hematology/oncology at Quest in San Juan Capistrano, California. He also held management positions at Johnson & Johnson Pharmaceutical and at Permanente Medical Group.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.